Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases by targeting Natural Killer T (NKT) cells [4] - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity being developed as an oral therapeutic for idiopathic pulmonary fibrosis [4] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus [4] - The company has a library of over 500 proprietary compounds to fuel its pipeline [4] Upcoming Events - Marc Hertz, PhD, CEO of GRI Bio, will present at the H C Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York, NY [1] - Management will be available for one-on-one meetings with qualified investors during the conference [2] - A video webcast of the presentation will be available on-demand starting September 9, 2024 at 7:00 AM ET on the company's website and will be archived for 90 days [3] Technology and Pipeline - GRI Bio's therapies target NKT cells, which are key regulators in the inflammatory cascade, to interrupt disease progression and restore immune system homeostasis [4] - Type 1 invariant (iNKT) cells play a critical role in propagating injury, inflammatory response, and fibrosis in inflammatory and fibrotic diseases [4] - The company's approach aims to fundamentally change the treatment of inflammatory, fibrotic, and autoimmune diseases [4]
GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference